Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction.

Abstract

BACKGROUND:

Androgen ablation is the first-line therapy for patients with metastatic prostate cancer (CaP). However, castration resistance will eventually emerge. In the present study, we have investigated the role of bone morphogenetic protein-6 (BMP-6) in the development of castration-resistant prostate cancer (CRPC) in the context of bone metastases.

METHODS:

We initially investigated the clinical course of 158 men with advanced CaP who were treated with primary androgen deprivation therapy. To elucidate the underlying mechanism of CRPC in the context of bone metastases, we examined the impact of bone stromal cells on CaP in the absence of androgens using a co-culture model.

RESULTS:

In the 158 patients, we found that the median time to prostate-specific antigen progression was significantly shorter when bone metastases were present (14 months (95% CI, 10.2-17.8 months) vs 57 months (95% CI, 19.4-94.6 months)). These results suggest that bone-tumour interactions may accelerate castration resistance. Consistent with this hypothesis, in vitro co-cultures demonstrated that CaP cells proliferated under an androgen-depleted condition when incubated with bone stromal cells. Mechanistically, gene expression analysis using quantitative polymerase chain reaction arrays showed a dramatic induction of BMP-6 by CaP cell lines in the presence of bone stromal cells. Further studies revealed that WNT5A derived from bone stromal cells induced the expression of BMP-6 by CaP cells; BMP-6 in turn stimulated cellular proliferation of CaP cells in an androgen-deprived media via a physical interaction between Smad5 and β-catenin. Intracellularly, WNT5A increased BMP-6 expression via protein kinase C/NF-κB pathway in CaP cell lines.

CONCLUSIONS:

These observations suggest that bone-CaP interaction leads to castration resistance via WNT5A/BMP-6 loop.

• Authors: G T Lee, D I Kang, Y-S Ha, Y S Jung, J Chung, K Min, T H Kim, K H Moon, J M Chung, D H Lee, W-J Kim, I Y Kim
• Journal: British journal of cancer (Br J Cancer) Vol. 110 Issue 6 Pg. 1634-44 (Mar 18 2014) ISSN: 1532-1827 [Electronic] England
• PMID: 24518599 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Androgen Antagonists
• Anilides
• BMP6 protein, human
• Bone Morphogenetic Protein 6
• Nitriles
• Proto-Oncogene Proteins
• Receptors, Androgen
• Tosyl Compounds
• WNT5A protein, human
• Wnt Proteins
• Wnt-5a Protein
• bicalutamide

Topics

• Adult
• Androgen Antagonists (therapeutic use)
• Anilides (therapeutic use)
• Bone Morphogenetic Protein 6 (biosynthesis, metabolism)
• Bone Neoplasms (metabolism, secondary, therapy)
• Cell Communication (physiology)
• Cell Growth Processes
• Cell Line, Tumor
• Humans
• Male
• Middle Aged
• Neoplasm Metastasis
• Nitriles (therapeutic use)
• Orchiectomy
• Prostatic Neoplasms, Castration-Resistant (metabolism, pathology, therapy)
• Proto-Oncogene Proteins (biosynthesis, metabolism)
• Receptors, Androgen (metabolism)
• Retrospective Studies
• Stromal Cells (pathology)
• Tosyl Compounds (therapeutic use)
• Wnt Proteins (biosynthesis, metabolism)
• Wnt-5a Protein